+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Review on different COVID-19 vaccines approved for Emergency Use Listing by WHO until 11 July 2022: characterization, pharmacological properties, mechanism of action and adverse events.

      In review
        1 , , 2
      ScienceOpen Preprints
      COVID-19, Corona disease, vaccines, WHO, pharmacological properties, adverse events


            Background: Since the outbreak of the novel Coronavirus in Wuhan and its transformation into a global pandemic, the main concern of medical systems has been to find vaccines to help the immune system overcome the virus or, at the very least, to prevent COVID-19 positive cases from deteriorating into serious conditions necessitating hospitalization. The pace of COVID-19 vaccine production accelerated, resulting in the development of the first FDA-approved vaccine (Pfizer vaccine) in less than a year. By July 6, 2022, WHO has approved 11 vaccines for emergency use. These vaccines differ in their characterization, pharmacological properties, and mechanism of action. Before vaccines can be used, their effectiveness and safety must be evaluated. Vaccine manufacturers strive for efficiency of at least 50%. To assess the vaccine's safety, manufacturers must report any adverse events that occur in trials before license approval and in populations after license approval.

            Main body of the abstract: The review article discussed the general approach for vaccine production, beginning with the pre-clinical stages and progressing to the approval and manufacturing stages, as well as the general types of vaccines. By July 11, 2022. WHO approved 11 vaccines for the COVID-19 emergency use listing. The review discussed these vaccines' characteristics, efficiency, shelf-life, storage temperature, structure, mechanism of action, and potential adverse events.

            Conclusion: According to the review article, all of the vaccines were able to stimulate immune response against the novel corona virus. Vaccine adverse events are typically similar and mild, disappearing spontaneously within a few days after vaccine administration.


            Author and article information

            ScienceOpen Preprints
            24 August 2022
            [1 ] Department of Microbiology, Faculty of science, Alexandria University, Egypt.
            [2 ] Department of Radiology, Faculty of Applied Medical Sciences, October 6 University,Egypt
            Author notes

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Medicine,Immunology,Public health,Infectious disease & Microbiology,Microbiology & Virology
            COVID-19,Corona disease,vaccines,WHO,pharmacological properties,adverse events


            Comment on this article